Essex Investment Management’s Corcept Therapeutics CORT Stock Holding History

Essex Investment Management’s Portfolio CORT Stock Details CORT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2019 Q1	–	Sell	-403,712	Closed	-$5.39M	–	488
2018 Q4	$5.39M	Sell	403,712 -29,419	-7%	-$389K	0.85%	22
2018 Q3	$6.07M	Sell	433,131 -206	-0%	-$2.88K	0.71%	31
2018 Q2	$6.81M	Sell	433,337 -1,287	-0.3%	-$22.4K	0.85%	23
2018 Q1	$7.15M	Sell	434,624 -14,088	-3%	-$261K	0.94%	20
2017 Q4	$8.1M	Buy	448,712 +144,611	+48%	+$2.62M	1.07%	17
2017 Q3	$5.87M	Sell	304,101 -74,745	-20%	-$1.11M	0.8%	23
2017 Q2	$4.47M	Buy	378,846 +49,541	+15%	+$538K	0.64%	33
2017 Q1	$3.61M	Buy	329,305 +97,038	+42%	+$852K	0.57%	45
2016 Q4	$1.69M	Buy	232,267 +59,878	+35%	+$469K	0.28%	99
2016 Q3	$1.12M	Buy	+172,389	New	+$1M	0.18%	140

Other funds holding CORT

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Federated Hermes Pittsburgh, Pennsylvania $61.5B AUM 30.7% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

ISL

Ingalls & Snyder LLC New York $2.83B AUM 21.61% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

CCM

Consonance Capital Management New York $7.28M AUM 43.59% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return

Bank of New York Mellon New York $609B AUM 40.19% 1-Year Est. Return

Essex Investment Management's CORT Position: Q1 2019 in Review

Essex Investment Management sold out of Corcept Therapeutics (CORT) in Q1 2019, closing a stake of 403,712 shares — an estimated $5.39M sold.

Essex Investment Management first reported a position in CORT in Q3 2016 and held it in 10 quarters. The position peaked at $8.1M in Q4 2017. 208 funds tracked by Wall St. Rank hold CORT as of Q1 2019.

Essex Investment Management reported no remaining Corcept Therapeutics position as of Q1 2019 after selling out during the quarter.
Essex Investment Management sold 403,712 Corcept Therapeutics shares in Q1 2019, an estimated $5.39M.
Essex Investment Management first reported a position in Corcept Therapeutics in Q3 2016 and held it in 10 quarters.
Essex Investment Management's Corcept Therapeutics position peaked at $8.1M in Q4 2017.
208 funds tracked by Wall St. Rank held Corcept Therapeutics as of Q1 2019.

Based on Essex Investment Management's 13F filing for Q1 2019, filed 15 May 2019.